Company Overview
About Timberlyne Therapeutics
Timberlyne Therapeutics launched in January 2025 with $180 million in Series A financing from Abingworth, Bain Capital Life Sciences, and Venrock, developing CM313 — an anti-CD38 monoclonal antibody with differentiated complement-dependent cytotoxicity properties. CM313 achieved a 95% response rate in treatment-refractory immune thrombocytopenia (ITP) in data published in the New England Journal of Medicine in 2025 — a 95% response rate in refractory patients is exceptional in autoimmune disease.
Business Model & Competitive Advantage
CD38 is a cell surface protein highly expressed on plasma cells that produce pathogenic antibodies in multiple autoimmune conditions. Existing anti-CD38 drugs (daratumumab, isatuximab) are approved for multiple myeloma but have different cytotoxicity mechanisms than CM313. Timberlyne's complement-dependent cytotoxicity approach may provide more complete plasma cell depletion in autoimmune settings where existing anti-CD38 drugs have shown incomplete responses.
Competitive Landscape 2025–2026
In 2026, Timberlyne is advancing CM313 across multiple autoimmune indications beyond ITP, leveraging the NEJM data as a clinical proof-of-concept for the CD38 target in autoimmunity more broadly. The combination of high-quality clinical data in a prestigious journal and a multi-indication expansion strategy positions Timberlyne for significant 2026-2027 clinical milestones.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Timberlyne Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Timberlyne Therapeutics has achieved $180M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Timberlyne Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Timberlyne Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Timberlyne Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Timberlyne Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →